Blume-Jensen Peter bought ACRV
January 14, 2026 · Form 4 insider transaction
Blume-Jensen Peter bought 49,000 shares of Acrivon Therapeutics, Inc. at $1.68 per share, a transaction worth $82.1K. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 2 days after the transaction.
Footnotes
The price reported in Column 4 above reflects the weighted average purchase price. This transaction was executed in multiple trades at prices ranging from $1.66 to $1.68, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in footnote 1 of this Form 4.; These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.